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Abstract
The development of novel drugs specifically directed at the ion channels underlying particular features of cardiac action potential
(AP) initiation, recovery, and refractoriness would contribute to an optimized approach to antiarrhythmic therapy that minimizes
potential cardiac and extracardiac toxicity. Of these, Kþ channels contribute numerous and diverse currents with specific actions
on different phases in the time course of AP repolarization. These features and their site-specific distribution make particular Kþ
channel types attractive therapeutic targets for the development of pharmacological agents attempting antiarrhythmic therapy in
conditions such as atrial fibrillation. However, progress in the development of such temporally and spatially selective antiar-
rhythmic drugs against particular ion channels has been relatively limited, particularly in view of our incomplete understanding of
the complex physiological roles and interactions of the various ionic currents. This review summarizes the physiological prop-
erties of the main cardiac potassium channels and the way in which they modulate cardiac electrical activity and then critiques a
number of available potential antiarrhythmic drugs directed at them.
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Introduction
Orderly propagation of cardiac electrophysiological excitation
and recovery depends on a normal sequence of cardiac action
potential (AP) generation through its component myocytes. The
depolarization and repolarization of AP is mediated by multiple,
interacting, inward and outward currents mediated by different
ion charge carriers dependent on the action of specific mem-
brane ion channels (Figure 1). The initial depolarization phase
takes the form of a rapid upstroke and is mainly driven by inward
Naþ current (INa) through voltage-gated sodium channels
(Nav1.5). The succeeding plateau phase is dominated by inward
Ca2þ current (ICa). The resulting entry of extracellular Ca
2þ
induces release of sarcoplasmic reticular Ca2þ stores, thereby
activating excitation–contraction coupling. Repolarization, ulti-
mately returning the membrane to the resting potential, is prin-
cipally driven by outward current through voltage-gated Kþ
channels (Kv).
1 Kþ channel activity is thus a principal determi-
nant of AP duration (APD) as it limits the depolarization dura-
tion and therefore both the time course of the Ca2þ-mediated
contraction and the refractory period. There are numerous and
diverse Kþ channels types, each with particular kinetic and
voltage-dependent properties. These result in numerous and
diverse current contributions, each with specific roles at different
phases of repolarization. Together these determine the relatively
prolonged but finely tuned repolarization time course and the
repolarization reserve following recovery of the resting mem-
brane potential. The repolarization reserve refers to the partly
overlapping function of these currents, namely, IKr, IKs, and IK1,
that gives a limited level of redundancy to the system.2 The
kinetics of repolarization varies greatly with cardiac region and
species. This reflects variations in the occurrence and density of
the different Kþ channel subtypes. All these characteristics sug-
gest that explorations of Kþ channels may yield a useful group
of pharmacological targets for arrhythmic conditions.
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Potassium Channels
Kþ channels represent the most functionally diverse cardiac ion
channel type.3-6 Together, they tightly regulate cardiac repolar-
ization, thus ensuring stable and consistent AP signaling. The
different Kþ channel types have overlapping functions,2,7
resulting in some degree of functional redundancy,2 which in
turn contributes to repolarization reserve. Table 1 summarizes
their encoding genes with their chromosomal locations and the
structural properties of their pore-forming a- and accessory
b-subunits. The a-subunit of different Kþ channel types all
possess a conserved pore-forming region allowing Kþ move-
ment across the plasma membrane down an electrochemical
gradient possessing a selective permeability to Kþ attributable
to a specific structural motif. They may also exhibit gating
mechanisms responsive to membrane depolarization and
ligand-binding sites whose occupancy could alter channel con-
formation. Finally, individual monomeric a-subunits may
assemble into functional dimers or tetramers due to the pres-
ence of one or more subunit-assembly domains.6,8-10 Kþ chan-
nel a-subunits fall into 3 structural types based on subunit
topology (Figure 2). The first has 1 pore-forming region with
6 or 7 transmembrane regions (Figure 2A), the second has 1
pore-forming region and 2 transmembrane regions (Figure 2B),
and the third has 2 pore-forming and 4 transmembrane regions
(Figure 2C).5,6,10
Kþ channel b-subunits encompass many molecular groups,
such as adenosine triphosphate (ATP)–binding cassette
transport-related proteins (eg, sulfonylurea receptors) for
inward rectifiers, cytoplasmic proteins (KChIP, KChAP, and
Kvb1-3), and single transmembrane spanning proteins
(minK).10 These b-subunits form complexes with the a-subunits
and can modify the channel’s functional properties. For exam-
ple, Kvb subunits can alter channel trafficking and the kinetics
of current activation and inactivation when interacting with
Kv1.5.
11 More specifically, Kvb2.1 and Kvb4.1 behave as
chaperone proteins.12 Furthermore, the N-terminus of Kvb1.2
and Kvb1.3 has an inactivation domain resembling the inacti-
vation particle of the a-subunit, allowing it to modulate
2channel inactivation.12-14
Figure 1. The ventricular action potential as a paradigm for cardiac
electrophysiological activity. In the resting state, the voltage of the cell
intracellular space is negative to the external environment. This
reflects its higher Kþ but lower Naþ and Ca2þ concentrations and its
lower membrane permeability to Naþ and Ca2þ in comparison to Kþ.
Kþ efflux from the cell is then controlled by the inward rectifier Kþ
channel (IK1). When excitation threshold is reached, a large Na
þ influx
(INa) into the cell through Na
þ channels produces phase 0 depolariza-
tion. This is followed by activation of fast and slow transient outward
Kþ currents (Itof and Itos, respectively) mediating a K
þ efflux driving a
rapid phase 1 repolarization. There is also an activation of a depolar-
izing inward Ca2þ current through L-type Ca2þ channels (ICa), which
initiates excitation contraction coupling. The reduced membrane Kþ
permeability due to IK1 rectification combined with ICa maintains the
action potential phase 2 plateau phase. Phase 3 repolarization is driven
by Kþ efflux through the rapid and slow delayed rectifier Kþ channels
(IKr and IKs, respectively), as well as IK1. At the end of phase 3, the Na
þ
and Ca2þ that have accumulated in the cells are removed by the Naþ,
Kþ pump, and the Naþ, Ca2þ exchanger (NCX). The atrial action
potential shows greater contributions to recovery from the ultrarapid
delayed rectifier outward currents (IKur) and acetylcholine-activated
inward rectifying Kþ channel (IKACH). Adapted with permission from
Huang.1
Table 1.Molecular Details and Activation Mechanisms of the Cardiac
Potassium Channels.2
Current Gene
Chromosomal
Location
Associated
Protein
Type of
Subunit
Itof KCND3 1p13.2 Kv4.3 a
KCNIP2 10q24.32 KChIP2 b
KCNE3 11q13.4 MiRP2 b
Itos KCNA4 11p14.1 Kv1.4 a
IKs KCNQ1 11p15.5-p15.4 Kv1.7.1/KvLQT1 a
KCNE1 21q22.12 minK b
AKAP9 7q21.2 AKAP-9 b
IKr KCNH2 7q36.1 Kv11.1/hERG a
KCNE2 21q22.11 MiRP1 b
IK1 KCNJ2 17q24.3 Kir2.1/IRK1 a
KCNJ12 17p11.2 Kir2.2/IRK2 a
IKATP KCNJ8 12p12.1 Kir6.1 a
KCNJ11 11p15.1 Kir6.2 a
ABCC9 12p12.1 SUR2A/SUR2Ba b
IKur KCNA5 12p12.32 Kv1.5 a
KCNAB1-B3 N/A Kvb1-3 b
IKAch KCNJ3 2q24.1 Kir3.1/GIRK1 a
KCNJ5 11q24.3 Kir3.4/GIRK4 a
Abbreviations: IK1, inward rectifier K
þ current; IKACH, acetylcholine-activated
inward-rectifier Kþ current; IKATP, ATP-sensitive K
þ current; IKr, rapid
component of the delayed rectifier Kþ current; IKs, slow component of the
delayed rectifier Kþ current; IKur, ultrarapid component of the delayed rectifier
Kþ current; Itof, fast transient outward K
þ current; Itos, slow transient outward
Kþ current.
aSUR2A and SUR2B are splice variant of ABCC9 and considered as cardiac
(SUR2A) and vascular (SUR2B) isoforms.
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Cardiac Potassium Currents
Cardiac Kþ channels vary in their permeability properties,
membrane potential dependence, and their opening or closing
activation and inactivation kinetics. The major currents are
classified into the transient outward currents, delayed rectifier
outward currents, and the inward rectifiers (Figure 3).
Advances in electrophysiological and molecular biology
techniques have demonstrated additional currents that may fall
outside this basic classification. Some brief notes on the major
cardiac Kþ currents, their role in the cardiac AP, and their
functional importance follow.
Transient outward Kþ (Ito1) currents. When first described, the
transient outward currents (Ito) were attributed to 2 distinct
channels, one blocked by 4-aminopyridine (4-AP) and unaf-
fected by extracellular Ca2þ (Ito1) and the other not blocked by
4-AP but sensitive to Ca2þ (Ito2).
6 Ito drives the initial rapid
repolarization phase of the AP. Regions with shorter APDs,
such as the epicardium, right ventricle, and septum, have
higher Ito expression. It was later discovered that Ito2 is a
Cl- rather than a Kþ current.15 Further characterizations sub-
divided Ito1 into fast (Itof) and slow (Itos) currents (Figure 3).
Itof predominates in the atria, whereas both Itof and Itos occur
in the ventricles.16 While Itos requires longer recovery times,
its classification as “slow” is relative only to Itof. Thus, both
Itof and Itos channels activate and inactivate rapidly in com-
parison to the corresponding processes in other Kþ chan-
nels.15 Due to differences in the biophysical properties of
Itof and Itos, the existence of molecular heterogeneity between
these 2 channels has been previously suggested.15
Ultrarapid delayed rectifier currents (IKur). In addition to Ito, the
ultrarapid delayed rectified Kþ current (IKur) plays a role in the
initial rapid phase 1 AP repolarization. IKur activates rapidly in
under 10 milliseconds at voltages in the plateau range and
deactivates slowly over the course of the AP.17-19 IKur is the
predominant delayed rectifier current for the atria and thus
results in the shorter APD seen in the atria compared to the
ventricles.10,16,17,19 Where IKur is present, its channels are not
evenly distributed over the myocyte surface but instead found
at high densities in the intercalated disk.6 This pattern of dis-
tribution is often disrupted after cardiac ischemic damage.10
The selective presence of IKur in the atria makes it an interest-
ing target for atria selective therapy, whereby inhibition of IKur
would prolong the APD in the atria but not the ventricles.4
Rapid delayed rectifier Kþ currents (IKr). The voltage-gated rapid
delayed rectifier outward Kþ current (IKr) is critical to phase 3
repolarization. It shows a relatively rapid activation with depo-
larization. However, its inactivation rate is around 10 times
faster than its activation rate due to voltage-dependent C-type
inactivation. This renders it relatively nonconducting in phases
1 and 2 of the cardiac AP.20-23 Thus, although termed a delayed
rectifier current, it also shows an inward rectification property
at positive potentials.22,24 However, with the end of phases 1
and 2, as the membrane potential becomes negative to 0 mV,
IKr becomes activated once again, but the deactivation during
this phase is much slower. This results in a large outward Kþ
efflux during phase 3 repolarization.2,10 IKr is found in both
human atria and ventricles but is differentially expressed with
higher levels in the left atrium and ventricular endocardium.16
Slowly activating delayed rectifier Kþ current (IKs). Cardiac repo-
larization is also influenced by a third, slowly activating
delayed rectifier Kþ current (IKs). IKs slowly activates at poten-
tials positive to 20 mV. Unlike IKr, IKs barely inactivates25,26
and consequently accumulates over phase 2 repolarization, sig-
nificantly influencing phase 3 repolarization.2 This feature of
IKs is particularly important during atrial and ventricular APs of
long duration. It is also involved in APD shortening during
physiological increases in heart rate. An increase in heart rate
thus reduces the time required for IKs inactivation. In conse-
quence, more IKs accumulates, leading to a steeper drop in the
Figure 2. Structure of different cardiac potassium channel species:
Schematic representation of selected potassium channel a-subunits.
A, The 6-transmembrane 1-pore-region voltage-dependent Kþ chan-
nel (Kv) a-subunits mediating IKur, Ito, IKs, IKr, and If. B, The
2-transmembrane 1-pore-region inward rectifying Kþ channel (Kir)
a-subunits mediating IK1, IKATP, and IKAch. C, The 4-transmembrane
2-pore-region Kþ channel (K2P) mediating “leak” K
þ currents. The
arrows indicate the location of the pore-forming region(s). HCN indi-
cates hyperpolarization-activated cyclic nucleotide-gated channel; If,
inward rectifier mixed Naþ and Kþ “funny” current; IK1, inward rec-
tifier Kþ current; IKACH, acetylcholine-activated inward rectifier K
þ
current; IKATP, ATP-sensitive K
þ current; IKr, rapid component of the
delayed rectifier Kþ current; IKs, slow component of the delayed
rectifier Kþ current; IKur, ultrarapid component of the delayed recti-
fier Kþ current; Ito, transient outward K
þ current. Reprinted with
permission from Giudicessi and Ackerman. Macmillan Publishers Ltd,
copyright 2012.3
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repolarization rate.27,28 Blocking IKs results in an APD prolon-
gation at increased heart rates.21,28 Inhibition of IKs will
increase the vulnerable window for reactivation of voltage-
gated Ca2þ channels, thereby increasing the risk of arrhythmic
trigger events.2 IKs is found in all cardiac cell types, but its
expression is significantly reduced in the mid-myocardial wall;
this accounts for the long APD seen in this region.16
Inward rectifier Kþ current (IK1) . The inward rectifier K
þ current
(IK1) functions over a narrow membrane potential range. Its
rectifying property results in a marked reduction in IK1 con-
ductance at positive, depolarized, membrane potentials and an
increase in IK1 at negative membrane potentials, with the effect
of stabilizing the membrane resting potential close to the Kþ
equilibrium potential (EK).
10 The channel mediating IK1 does
not show voltage-dependent gating and does not possess a
voltage sensor. Nevertheless, IK1 modulation associated with
movement of Mg2þ and polyamines results in an indirect sen-
sitivity to voltage.29-32 Between phase 0 and phase 2 of the AP,
the membrane potential is more positive than 20 mV, and at
this potential, there is no conductance of IK1 as the channel is
inhibited by Mg2þ and polyamines. The resulting marked
inward rectification property limits the outward current at these
positive potentials. This in turn minimizes the inward depolar-
izing current, which confers energetic efficiency for AP gen-
eration as it minimizes changes to ionic gradients that would
need to be restored.16 As the potential returns to more negative
values (typically around 40 mV), the inhibition by Mg2þ and
polyamines is reversed. IK1 conductance then resumes and this
contributes to phase 3 cardiac repolarization.31 IK1 occurs in
both atria and ventricles and is thereby involved in setting their
resting membrane potentials. Channels conducting IK1 are
expressed in greater density in the ventricles, making the ven-
tricles less susceptible to pacemaker influence.16
Acetylcholine-activated Kþ current (IKACH). The inwardly rectifying
acetylcholine (ACh)-activated Kþ current (IKACH) is regulated
by G proteins rather than voltage gating. Cardiac parasympa-
thetic nerve endings release ACh, thereby activating M2 mus-
carinic receptors. This reduces the depolarizing effect of the
pacemaker current (If), reducing firing rates of pacemaker cells
and in turn reducing heart rate.6 Acetylcholine also opens
muscarinic-sensitive IKACH channels allowing the inward rec-
tification of Kþ. The inward rectifying current shortens the AP
and hyperpolarizes the membrane potential.16 Membrane
hyperpolarization reduces the rate at which the sinoatrial and
atrioventricular (AV) nodes drive pacemaker depolarization in
addition to reducing AV conduction velocity.6,33 IKACH is
thought to be specific to the atria,2 but there has been a sug-
gestion that it may exist both in the atria and ventricle,16 but
with densities 6 times greater in the atria than the ventricles.34
ATP-activated Kþ current (IKATP). The ATP-activated K
þ current
(IKATP) occurs at both the sarcolemmal (sarc-KATP) and mito-
chondrial inner membrane (mito-KATP) of cardiomyocytes.
The sarc-KATP channels are highly expressed in cardiomyo-
cytes and are composed of Kir6.2 and SUR2A subunits. There
may also be contributions from Kir6.1 and SUR1.
35 In con-
trast, although the subunits of mito-KATP channels have been
difficult to identify due to the challenge of isolating pure
Figure 3. Classification of Kþ currents: General classification of the main cardiac Kþ currents. The relatively new additions to the Kþ channel
family (Ca2þ-activated Kþ current [IKCa] and 2-pore domain K
þ current [IK2p]) have not been grouped under this scheme. Most K
þ currents are
grouped according to the direction of their overall rectification property. In some instances, this may vary. With the inward rectifying Kþ
channels, the name refers to the unusual characteristic whereby net potassium flow is into the cell at potentials lower than the reversal potential
where channel conductance is high. As the channel potential becomes more positive, channel conductance decreases. Net ion flow direction
reverses at the reversal potential, meaning that net potassium flow is outward at potentials more positive than this. Therefore, at depolarized
potentials, potassium loss from the cell is low as conductance through the channel is low.
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mitochondrial membrane fractions, ROMK2 pore-forming
subunits and SUR2 regulatory subunits have been suggested
to contribute.36,37
Both channels are controlled by ATP and are thus directly
responsive to the cell’s metabolic status, thereby influencing
cell membrane potential.6 IKATP is inhibited by physiological
intracellular ATP levels, but this reverses with ATP depletion.
Thus, under normal energetic circumstances, there is limited
IKATP current. However, under both physiological and patho-
logical conditions that reduce ATP, there is increased IKATP
current that is essential for adaptation to stress. For example,
compared to wild-type controls, mice lacking Kir6.2-containing
KATP channels perform less well in acute treadmill exercise
testing.38 The increased IKATP has a cardioprotective role in
ischemia by shortening the cardiac AP, thus limiting calcium
influx into the cytosol.39-41 Specifically, studies have suggested
that mito-KATP rather than sarc-KATP channel opening has an
energy-modulating property that confers cardioprotection in
ischemic hearts.42,43
In some situations, the IKATP-mediated APD shortening and
corresponding heterogeneities in repolarization can create a
substrate for cardiac reentry arrhythmia. In other situations,
KATP channel openers have been described to have antiarrhyth-
mic effects,44-48 and evidence suggests that activation and
block of KATP can be pro- or antiarrhythmic depending on the
arrhythmogenic mechanism in different animal models.49 For
example, selective sarcolemma KATP channel blockers, such as
HMR 1883, confer antiarrhythmic effects in the short term,50
although this could be metabolically disadvantageous in the
long term due to the abolished adaptive response to stresses.
Finally, it is important to note that the channel involved in the
conductance of IKATP is also thought to be involved in the
regulation of smooth muscle tone and insulin secretion in pan-
creatic b-cells.6
Other Kþ channel family: Ca2þ-activated Kþ current (IKCa), 2-pore
domain Kþ current (IK2p), and hyperpolarization-activated cyclic
nucleotide-gated channels. Recently, several further currents
have been characterized. The Ca2þ-activated Kþ current, also
known as the small conductance Ca2þ-activated Kþ (SK) cur-
rent (IKCa), and the 2-pore domain K
þ current (IK2p) have
attracted considerable physiological and pharmacological
interest. IKCa was initially thought to not exist in the human
heart.51 However, subsequent studies demonstrated the pres-
ence of IKCa, with a higher density in the atria than the ven-
tricle. Various subtypes of Ca2þ-activated Kþ channels exist in
different tissues; the channel subtype conducting the cardiac
IKCa is the SK channel.
51,52 In neuronal cell, SK channels that
are involved in modulating the tonic firing frequency and
activation of these channels cause membrane hyperpolariza-
tion, thus limiting neuronal AP firing frequency.51 In contrast,
cardiac SK channels and consequently IKCa are involved in
late AP repolarization, controlling the resting membrane
potential in human atria.52 IKCa appears to not play physiolo-
gically significant roles in the ventricle.52 IKCa is accordingly
of particular pharmacological interest for atrial fibrillation
(AF) therapy. Thus, IKCa occurs during late repolarization,
when the atrial AP is susceptible to irregular or abnormal
excitation such as that resulting from early after-
depolarizations (EADs).51
IK2p contributes to the background current, the resting mem-
brane potential, and cellular excitability. The channel involved
in the conductance of this current has no voltage dependence,
but its activity is modulated by lipids, particularly fatty acids,
pH, drugs, particularly local and inhalation anesthetics, and
membrane stretch.53,54 These mediators act upon the channel
via secondary messenger phosphorylation.55 IK2p is a back-
ground current that persists through all phases of the cardiac
AP. It thus stabilizes the membrane potential toward Em. IK2p
may also prevent the occurrence of EADs, and it may be
involved in fine-tuning of Naþ channel availability for phase
0 depolarization.56 The current has been found to occur selec-
tively in the atria and AV node, thereby making it a target for
drug development.57-59 Although not entirely new but only
recently well characterized, the hyperpolarization-activated
cyclic nucleotide-gated (HCN) channel is instrumental in con-
ducting the inward funny current (If) in the heart. The channel
is activated by the hyperpolarization of the membrane and is
additionally stimulated by intracellular cyclic nucleo-
tides.60,61 The generation of If is attributable to the inward
permeability of both Naþ and Kþ and occurs at threshold
close to the resting membrane potential.62 Although the HCN
channel under physiological circumstances conducts both
Naþ and Kþ, the primary sequence of the HCN pore region
suggests that it is primarily related to a selective potassium
channel.63 In certain pathological conditions such as AF and
myocardial infarction, If is increased unusually outside the
pacemaker cells, leading to increased propensity to arrhyth-
mia. Thus, targeting the If in such pathological conditions has
proven to be therapeutically advantageous.64
Cardiac Kþ Channel as Targets
for Drug Development
Although there have been significant recent advances in the
development and use of cardiological devices and procedures
directed at arrhythmic conditions, antiarrhythmic drugs con-
tinue to be important whether by themselves or as adjunct
therapy to such interventions. These include situations involv-
ing acute management of potentially fatal arrhythmic events,
particularly where such procedures are contraindicated. Yet
progress in antiarrhythmic drug development has been rela-
tively limited. This likely reflects a lack of understanding of
cardiac arrhythmic mechanisms. However, recent develop-
ments of our understanding of the role of the ion channels
in normal AP generation have led to a specific interest into
ion channels and their associated currents whose abnormal
activity potentially leads to arrhythmia. This would encourage
interest in the development of cardiac ion channel activator or
blockers directed at modulating the cardiac AP or its refrac-
tory period. Introduction of drugs acting specifically on ion
channels would optimize the efficacy of therapeutic actions
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on arrhythmogenic tendency, while minimizing problems
arising from potential cardiac and extracardiac toxicity. Kþ
channels play a vital role in cardiac AP repolarization and
thus naturally form potential targets for the development of
ion channel-specific antiarrhythmic therapy, such as for AF.
However, a limitation of this approach is that arrhythmic
conditions, such as AF, are heterogeneous and the efficacy
of targeting ion channels varies according to the cause and
extent of the arrhythmia.
This is complicated by the fact that in various physiologi-
cal and pathological conditions, remodeling of Kþ channel
expression can occur, which can alter the AP and increase the
risk of sudden cardiac death.65 For example, AF is maintained
and progressed partly due to electrical remodeling, mediating
APD shortening.66 Thus, in chronic AF, there is upregulation
of IK1, IKs, and IK2P3.1, which offsets the possible downregu-
lation of IKur and Ito.
67-69 Nevertheless, the experimental evi-
dence for the reduction in IKur during remodeling is
conflicting, as some reports suggest reduced IKur density
70,71
and others suggest no change.72,73 It has been suggested that
receptor-activated IKACH (rIKACH) mediates AF induced by
vagal stimulation, while constitutive IKACH (c IKACH) devel-
ops in the time course of AF remodeling.67,74
In physiological cardiac hypertrophy, induced by chronic
exercise, for example, there is an increase in IK density.
75 This
contrasts with pathological cardiac hypertrophy caused by
pressure overload where a reduced IK density is noted that
was attributable to cellular hypertrophy rather than gene
expression changes in Itof and IK1.
76 In heart failure, AP pro-
longation is associated with downregulation of several genes,
leading to reduced Itof, IKs, IKr, and IK1.
65,77,78 Considering the
changes in Kþ channel expression in remodeling is clinically
important as the sensitivity and efficacy of blocking these
channels will change.
Table 2 outlines selected drugs that have been experimen-
tally proven to target different Kþ channels, using either native
cardiac myocytes or human cell line expression systems. Some
of these drugs presently in clinical use have been primarily
developed for other ion channels such as the Naþ or Ca2þ
cardiac ion channel but have corresponding effects on Kþ
channels. Several drugs have been proposed to be selective to
specific Kþ channels, such as A935142, XEN-D0103, and
XEN-D0101. However, despite promising experimental find-
ings, many of these drugs have not progressed to clinical use.
This may be attributable to limitations associated with experi-
mental studies. Expression systems can often produce off-
target effects or nonspecific interactions which may mask the
true effect of these drugs. Additionally, expression systems
may run the risk of either overexpressing or underexpressing
the channel of interest. On the other hand, native cardiac myo-
cytes, while more physiologically representative, may not pro-
vide the right platform for the study of specific targets.
Additionally, acquisition of viable native cardiac myocytes
from a minimally heterogeneous population remains a chal-
lenge, and it is widely accepted that channel functions can
differ by gender and age. Consequently, while experimental
studies may suggest potentially promising options to selec-
tively target Kþ channels, the translational capacity of such
studies remains limited.
Furthermore, these activators and blockers often target more
than 1 Kþ channel species and thus are not entirely spe-
cific.10,122 However, a large proportion of these drugs also
typically target IKr (known to be present in all cardiac regions)
and as such do not constitute ideal candidates for targeted
therapy. Nevertheless, mechanisms of cardiac arrhythmia are
likely to be region dependent. Drugs that may be antiarrhyth-
mic in some cardiac regions may potentially be pro-arrhythmic
in others. Thus, the presence of atrial-specific Kþ channels has
provided focus on developing drugs that could specifically
Table 2. Selected Pharmacological Agents Affecting the Human Kþ
Channels.
Current
Pharmacological Agent (Expression System),
Reference
Activators
IKr A-935142 (HEK),
79 ICA-105574 (HEK),80 NS1643
(HEK),81 PD-118057 (HEK)82
IKs Ephedrine (HEK),
83 Tanshinone IIA (HEK)84
IKca NS1619 (HEK)
85
Blockers
Ito Chromanol 293B (nHVM),
86 Flecainidea (nHAM)87
IKur Amiodarone
a (HEK),88 Bepridil (HEK),88 DPO-1
(nHAM),89 MK-0448 (nHAM),90 NIP-142
(HEK),91 Papaverine (nHAM),92 Pimozide
(HEK),93 Sertindole (HEK),94 XEN-D0103
(nHAM)95
IKr Cocaine (HEK),
96 Fluvoxamine (HEK),97
Ketoconazole (HEK),98 Ketanserin (HEK),99
Ziprasidone (HEK)100
IKs HMR 1556 (HEK),
101 SKF-96365 (HEK)102
IKACH NIP-151 (HEK),
103 U73122/U73343 (HEK)104
IKATP 5-Hydroxydecanoate (HEK),
105 HMR1098 (HEK)105
Ito, IKur AVE-0118 (nHAM),
106 Acacetin (nHAM),107
Ambasilide (nHAM),108,109 4-aminopyridine
(nHAM),87 Diltiazemb (nHAM),110
Docosahexaenoic acid (nHAM),111
Eicosapentaenoic acid (nHAM),111 Nifedipineb
(nHAM),110 Quinidinea (nHAM),87 Raloxifene
(nHAM),112 U50488 H (nHAM),113 XEN-D0101
(nHAM),114 Vernakalant (RSD1235) (HEK)115
Ito, IKur, IK1 Propafenone
a (nHAM)116
Ito, IKur, IKr,
IKs
Clotrimizole (nHAM)117
Ito, IKur, IKr,
IKs, IK1
Azimilide (nHAM)118
IKur, IKr Cisapride (HEK),
119 Verapamilb (nHAM, HEK)120,121
IKr, IKs Sotalol (nHAM)
21,108
Abbreviations: nHAM, native human atrial myocyte; HEK, human embryonic
kidney; nHVM, native human ventricular myocyte; IK1, inward rectifier K
þ
current; IKr, rapid component of the delayed rectifier K
þ current; IKACH,
acetylcholine-activated inward rectifier Kþ current; IKATP, ATP-sensitive K
þ
current;; IKs, slow component of the delayed rectifier K
þ current; IKur,
ultrarapid component of the delayed rectifier Kþ current; Ito, transient
outward Kþ current; IKCa, small conductance Ca
2þ-activated Kþ (SK) current.
aPrimary Naþ channel blocker.
bPrimary Ca2þ channel blocker.
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increase refractory periods, thus preventing atrial reentry
arrhythmia, which is the most common mechanism for AF.123
Of ion channels specific to the atrium that might offer spe-
cific therapeutic targets, the channel conducting IKur tends to
prolong repolarization and effective refractory period (ERP)
without altering QT intervals.124,125 The experimental drugs
AVE0118 and XEN-D101 are thought to be IKur selective
blockers with both prolonging APD in atrial tissue from
patients with permanent AF in common with the known IKur
blocker 4-AP.106-129 However, a subsequent “first-in-human”
study using the highly selective IKur blocker MK-0448
(N-f6-[(1S)-1-(4-fluorophenyl)-2,2-di (pyridine-3-1) ethyl]
pyridine2ylgmethane sulfonamide) did not reveal any increase
in atrial ERP. This led to the conclusion that selective blocking
of IKur may have limited clinical value.
130 IKACH channels are
also atrium specific or at least predominantly occur in the atria
and have minimal physiological function in the ventricle.129
Opening of the IKACH channel will lead to shortening of atrial
APD and thus increase the likelihood of AF. Therefore, block-
ing the opening of IKACH channels will prevent such shortening
of APD with minimal effect on ventricular APD, in turn reduc-
ing the chances of AF. Several drugs block IKACH, but have
limited specificity. Nevertheless, selective blocking of IKACH
has been experimentally achieved using the compound
NTC-801. The compound was found to have selective antifi-
brillatory properties, achieved by prolonging the atrial
ERP.131 Another potential atrial-specific therapeutic target
of interest is the IKCa current conducted by SK channels. The
selective presence of this current in the atria has recently led
to several investigative drugs beings explored. NS8593 is a
selective SK channel inhibitor demonstrating significant atrial
antiarrhythmic effects in canine and equine experimental
models. Experiments using human atrial cardiac myocytes
from patients with normal sinus rhythm demonstrated reduc-
tion in Kþ currents and prolongation in APD. No such
changes were observed in intraventricular myocytes.52
Conclusion
There is currently an incomplete understanding of the cellular
physiological role of the various cardiac potassium currents
and their interacting effects and how dysregulation of their
function and expression can provide arrhythmogenic mechan-
isms. It is thought that the site-specific distribution of some Kþ
channels could allow targeted therapy to be more spatially
selective. However, complex electrical remodeling events that
occur in disease states may change channel expression levels to
the extent that the selectivity of the drug is hindered, making
even this potential therapeutic strategy challenging. Although
targeting ion channels responsible for discrete parts of the car-
diac AP to modulate the system towards a more physiological
state has therapeutic appeal, there are inherent difficulties in
developing successful drugs. This is because the ion channels
targeted are functionally complex and are interdependent, thus
adding a dynamic situation in which function and expression
are altered depending on the cell environment. Furthermore,
pathophysiological processes of arrhythmic disease may
involve functional alterations in 1 or more ion channels. Such
single or multiple ion channel functional abnormalities may
therefore warrant corresponding use of a single or multichannel
activator/blocker approach. However, this approach will only
be possible if we are able to identify the specific pathophysio-
logical process affecting individual patients (ie, is this arrhyth-
mic disease related to a single or multichannel abnormality).
Thus, although we may be able to develop single or multichan-
nel activators/blockers, actual clinical use will be dependent on
a detailed understanding of the exact arrhythmogenic mechan-
isms affecting individual patients, which thus far is limited.
Presently, decisions to use single or multichannel activators/
blockers are largely dependent on resolution of clinical signs or
the actual arrhythmia rather than a therapeutic approach target-
ing ion channel functional abnormality. Furthermore, the avail-
ability of truly specific ion channel activators/blockers is
limited as these agents tend to have off-target actions with
corresponding side effects, and this limits the clinical use of
selective agents. Focusing on understanding the system at a
cellular physiological level through further experimental and
computational modeling is needed to enable development of
novel insights at a pharmacological level.
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